Introduction
- The emergence of Multisystem Inflammatory Syndrome in Children (MIS-C) during the COVID-19 pandemic presented significant diagnostic challenges due to its phenotypic resemblance to Kawasaki Disease (KD).
- Both conditions present with persistent fever, systemic hyperinflammation, and mucocutaneous manifestations.
- Distinguishing these entities remains critical because management strategies and cardiac prognoses differ significantly.
Comparision
| Clinical Feature | Kawasaki Disease (KD) | Multisystem Inflammatory Syndrome In Children (MIS-C) |
|---|---|---|
| Age Of Onset | Infants and young children under 5 years; median age approximately 2 years. | Older children and adolescents; median age 8 to 11 years. |
| Ethnic Predisposition | Higher incidence in East Asian descent populations. | Disproportionately affects African, Afro-Caribbean, and Hispanic ancestry. |
| Etiology | Unknown trigger; likely ubiquitous agent. | Post-infectious immune dysregulation following SARS-CoV-2 infection. |
| Fever Duration | Prolonged, classically unremitting for greater than 5 days. | Prolonged, > 38.0°C for $\ge$ 24 hours, commonly lasting 3 to 5 days. |
| Shock And Hypotension | Exceedingly rare, occurring in less than 5% of cases. | Defining feature, occurring in 50–80% of cases requiring vasopressor support. |
| Gastrointestinal Signs | Mild vomiting or diarrhea; less common. | Prominent in 80-90% of cases; severe abdominal pain mimicking appendicitis. |
| Cardiac Pathology | Primary complication is coronary artery vasculitis causing destructive aneurysms. | Primary complication is acute myocarditis triggering cytokine-induced dysfunction. |
| Ventricular Function | Left ventricular systolic function typically remains preserved. | Moderate to severe left ventricular dysfunction commonly occurs. |
| Platelet Count | Characterized by marked thrombocytosis in the subacute phase. | Characterized by profound thrombocytopenia (<150,000/μL). |
| Lymphocyte Count | Normal or features mild decrease. | Profound absolute lymphopenia. |
| Specific Biomarkers | Mild D-Dimer elevation; moderately elevated Ferritin. | Massively elevated D-Dimer indicating coagulopathy; Ferritin >500–1000 ng/mL. |
| Cardiac Biomarkers | Troponin and BNP exhibit mild elevation. | Troponin and BNP/NT-proBNP demonstrate massive elevation. |
| Viral Serology | Typically negative for SARS-CoV-2 antibodies unless coincidental. | Universal positive IgG/IgM serology indicating past SARS-CoV-2 infection. |
| Standard Therapy | Intravenous Immunoglobulin (2 g/kg) combined with Aspirin. | Intravenous Immunoglobulin (2 g/kg) combined with Corticosteroids and low-dose Aspirin. |
Epidemiological And Clinical Divergence
- KD exhibits a well-documented predilection for young children of East Asian descent, suggesting underlying genetic susceptibility.
- MIS-C predominantly strikes school-aged children and teenagers, an age demographic where classic KD remains historically rare.
- While mucocutaneous manifestations such as conjunctivitis, strawberry tongue, and extremity edema define KD, they frequently manifest incompletely or transiently in MIS-C.
Cardiovascular Pathophysiology
- KD drives direct coronary artery vasculitis, threatening the patient with long-term arterial stenosis and thrombosis if aneurysms develop.
- MIS-C primarily triggers acute myocarditis resulting in significant, albeit typically transient, left ventricular dysfunction.
- Coronary artery dilation observed during MIS-C results primarily from vasodilation induced by the hyperinflammatory state, rendering giant aneurysms rare.
Laboratory Profile Divergence
- The complete blood count delivers the most reliable differentiating signature, termed the platelet paradox.
- KD universally associates with thrombocytosis during disease progression, while MIS-C features consumption coagulopathy leading to thrombocytopenia.
- MIS-C features a laboratory profile closely resembling Macrophage Activation Syndrome, characterized by profound lymphopenia, neutrophilia, and extreme Ferritin elevations.
Management Protocols
- Standard KD therapy relies strictly on Intravenous Immunoglobulin combined with Aspirin.
- MIS-C mandates aggressive upfront dual immunomodulation utilizing Intravenous Immunoglobulin and Corticosteroids like Methylprednisolone, alongside low-dose Aspirin.
- Severe MIS-C cases demonstrating refractory shock or high thrombosis risk uniquely require adjunctive anticoagulation utilizing Enoxaparin and targeted biological agents like Anakinra or Tocilizumab.